Bryan Luce

Summary

Affiliation: United BioSource Corporation
Country: USA

Publications

  1. ncbi Health technology assessment in the United States
    Bryan Luce
    United BioSource Corporation, Bethesda, Maryland 20814, USA
    Int J Technol Assess Health Care 25:33-41. 2009
  2. ncbi EBM, HTA, and CER: clearing the confusion
    Bryan R Luce
    United BioSource Corporation, Bethesda, MD, USA
    Milbank Q 88:256-76. 2010
  3. ncbi Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States
    Bryan R Luce
    United BioSource Corporation, 7101 Wisconsin Avenue, Suite 600, Bethesda, MD 20814, USA
    Vaccine 26:2841-8. 2008
  4. ncbi Can managed care organizations partner with manufacturers for comparative effectiveness research?
    Bryan R Luce
    United BioSource Corporation, 7101 Wisconsin Ave, Ste 600, Bethesda, MD 20814, USA
    Am J Manag Care 14:149-56. 2008
  5. ncbi What will it take to make cost-effectiveness analysis acceptable in the United States?
    Bryan R Luce
    MEDTAP Institute at United BioSource Corporation UBC, Bethesda, Maryland 20814, USA
    Med Care 43:44-8. 2005
  6. ncbi Value of biologic therapy: a forecasting model in three disease areas
    L Clark Paramore
    Center for Health Economics, Epidemiology and Science Policy, United BioSource Corporation, Lexington, MA 02420, USA
    Curr Med Res Opin 26:41-51. 2010
  7. ncbi The return on investment in health care: from 1980 to 2000
    Bryan R Luce
    United BioSource Corporation, Bethesda, MD 20814, USA
    Value Health 9:146-56. 2006
  8. ncbi Economic burden of heart failure: a summary of recent literature
    Won Chan Lee
    Abt Associates Inc.-HERQuLES, Bethesda, MD, USA
    Heart Lung 33:362-71. 2004
  9. ncbi The effect on social welfare of a switch of second-generation antihistamines from prescription to over-the-counter status: a microeconomic analysis
    Ya Chen Tina Shih
    MEDTAP International, Inc, Bethesda, Maryland 20814, USA
    Clin Ther 24:701-16. 2002
  10. ncbi Patient satisfaction with budesonide Turbuhaler versus triamcinolone acetonide administered via pressurized metered-dose inhaler in a managed care setting
    Kevin B Weiss
    Northwestern University Medical School, Chicago, Illinois, USA
    J Asthma 42:769-76. 2005

Detail Information

Publications14

  1. ncbi Health technology assessment in the United States
    Bryan Luce
    United BioSource Corporation, Bethesda, Maryland 20814, USA
    Int J Technol Assess Health Care 25:33-41. 2009
    ..To describe and explore the reasons for the current health technology assessment (HTA) landscape in the United States...
  2. ncbi EBM, HTA, and CER: clearing the confusion
    Bryan R Luce
    United BioSource Corporation, Bethesda, MD, USA
    Milbank Q 88:256-76. 2010
    ..The objective of this article is to clarify their definitions and the relationships among key terms and concepts...
  3. ncbi Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States
    Bryan R Luce
    United BioSource Corporation, 7101 Wisconsin Avenue, Suite 600, Bethesda, MD 20814, USA
    Vaccine 26:2841-8. 2008
    ....
  4. ncbi Can managed care organizations partner with manufacturers for comparative effectiveness research?
    Bryan R Luce
    United BioSource Corporation, 7101 Wisconsin Ave, Ste 600, Bethesda, MD 20814, USA
    Am J Manag Care 14:149-56. 2008
    ..To describe 2 published pragmatic or practical clinical trials (PCTs) as case studies illustrating successful partnerships between managed care organizations (MCOs) and pharmaceutical manufacturers...
  5. ncbi What will it take to make cost-effectiveness analysis acceptable in the United States?
    Bryan R Luce
    MEDTAP Institute at United BioSource Corporation UBC, Bethesda, Maryland 20814, USA
    Med Care 43:44-8. 2005
    ..It discounts many of the conventional arguments regarding the real obstacles to using CEA and suggests steps needed to make CEA more acceptable to US healthcare decision-makers...
  6. ncbi Value of biologic therapy: a forecasting model in three disease areas
    L Clark Paramore
    Center for Health Economics, Epidemiology and Science Policy, United BioSource Corporation, Lexington, MA 02420, USA
    Curr Med Res Opin 26:41-51. 2010
    ..Forecast the return on investment (ROI) for advances in biologic therapies in years 2015 and 2030, based upon impact on disease prevalence, morbidity, and mortality for asthma, diabetes, and colorectal cancer...
  7. ncbi The return on investment in health care: from 1980 to 2000
    Bryan R Luce
    United BioSource Corporation, Bethesda, MD 20814, USA
    Value Health 9:146-56. 2006
    ..12 to Dollars 38.00 for every additional dollar spent. Conclusion: The value of improved health in the US population in 2000 compared with 1980 significantly outweighs the additional health-care expenditures in 2000 compared with 1980...
  8. ncbi Economic burden of heart failure: a summary of recent literature
    Won Chan Lee
    Abt Associates Inc.-HERQuLES, Bethesda, MD, USA
    Heart Lung 33:362-71. 2004
    ....
  9. ncbi The effect on social welfare of a switch of second-generation antihistamines from prescription to over-the-counter status: a microeconomic analysis
    Ya Chen Tina Shih
    MEDTAP International, Inc, Bethesda, Maryland 20814, USA
    Clin Ther 24:701-16. 2002
    ..The US Food and Drug Administration (FDA) recently held a meeting to determine whether the status of second-generation antihistamines (SGAs) should be switched from prescription (Rx) to over-the-counter (OTC) status...
  10. ncbi Patient satisfaction with budesonide Turbuhaler versus triamcinolone acetonide administered via pressurized metered-dose inhaler in a managed care setting
    Kevin B Weiss
    Northwestern University Medical School, Chicago, Illinois, USA
    J Asthma 42:769-76. 2005
    ..Patients treated with budesonide were significantly more satisfied and compliant with their inhaled corticosteroid regimen compared with patients treated with triamcinolone acetonide...
  11. ncbi Evidence based? Caveat emptor!
    Earl P Steinberg
    Resolution Health Inc, San Jose, California, USA
    Health Aff (Millwood) 24:80-92. 2005
    ....
  12. ncbi Key principles for the improved conduct of health technology assessments for resource allocation decisions
    Michael F Drummond
    Centre for Health Economics, University of York, Heslington, York, UK
    Int J Technol Assess Health Care 24:244-58; discussion 362-8. 2008
    ..The principles are organized into four sections: (i) "Structure" of HTA programs; (ii) "Methods" of HTA; (iii) "Processes for Conduct" of HTA; and (iv) "Use of HTAs in Decision Making."..
  13. ncbi Effectiveness of budesonide administered via dry-powder inhaler versus triamcinolone acetonide administered via pressurized metered-dose inhaler for adults with persistent asthma in managed care settings
    Kevin B Weiss
    Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Clin Ther 26:102-14. 2004
    ..However, effectiveness and cost-effectiveness comparisons of available inhaled corticosteroids in real-life clinical settings are lacking...
  14. ncbi Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies
    Milton C Weinstein
    Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
    Value Health 6:9-17. 2003
    ..This report describes the consensus of a task force convened to provide modelers with guidelines for conducting and reporting modeling studies...